Pregabalin Mylan Pharma
Active Substance: pregabalin
Common Name: pregabalin
ATC Code: N03AX16
Marketing Authorisation Holder: Generics UK Limited
Active Substance: pregabalin
Authorisation Date: 2015-06-25
Therapeutic Area: Epilepsy Anxiety Disorders Neuralgia
Pharmacotherapeutic Group: Antiepileptics
Pregabalin Mylan Pharma is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
Generalised Anxiety Disorder
Pregabalin Mylan Pharma is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
What is Pregabalin Mylan Pharma and what is it used for?
Pregabalin Mylan Pharma is a medicine used to treat adults with the following conditions:
- neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with diabetes or herpes zoster (shingles), and central neuropathic pain, such as the pain experienced by patients who have had a spinal cord injury;
- epilepsy, where it is used as an ‘add-on’ to existing treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment;
- generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).
Pregabalin Mylan Pharma is a ‘generic medicine’. This means that Pregabalin Mylan Pharma is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Lyrica.
Pregabalin Mylan Pharma contains the active substance pregabalin.
How is Pregabalin Mylan Pharma used?
Pregabalin Mylan Pharma is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription. The recommended starting dose is 150 mg per day, divided into two or three doses. After three to seven days, the dose can be increased to 300 mg per day. Doses can be increased up to twice more until the most effective dose is reached. The maximum dose is 600 mg per day. Stopping treatment with Pregabalin Mylan Pharma should also be done gradually, over at least a week. Doctors may need to lower the dose in patients who have kidney problems.
How does Pregabalin Mylan Pharma work?
The active substance in Pregabalin Mylan Pharma, pregabalin, is similar in structure to the body’s own ‘neurotransmitter’ gamma‑amino butyric acid (GABA), but has very different biological effects. Neurotransmitters are chemicals that allow nerve cells to communicate with each other. The exact way that pregabalin works is not fully understood, but it is thought to affect the way that calcium enters nerve cells. This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in pain, epilepsy and anxiety.
How has Pregabalin Mylan Pharma been studied?
Because Pregabalin Mylan Pharma is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Lyrica. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.
What are the benefits and risks of Pregabalin Mylan Pharma?
Because Pregabalin Mylan Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Why is Pregabalin Mylan Pharma approved?
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Mylan Pharma has been shown to have comparable quality and to be bioequivalent to Lyrica. Therefore, the CHMP’s view was that, as for Lyrica, the benefit outweighs the identified risk. The Committee recommended that Pregabalin Mylan Pharma be approved for use in the EU.
What measures are being taken to ensure the safe and effective use of Pregabalin Mylan Pharma?
A risk management plan has been developed to ensure that Pregabalin Mylan Pharma is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pregabalin Mylan Pharma, including the appropriate precautions to be followed by healthcare professionals and patients.
Further information can be found in the summary of the risk management plan.
Other information about Pregabalin Mylan Pharma
The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Mylan Pharma on 25 June 2015.
For more information about treatment with Pregabalin Mylan Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.